As demonstrated in Figure 5A–5D, IT treatment (20, 40 and 80 μM) for 72 h markedly decreased the levels of survivin, BCL-XL, and MCL-1 in human melanoma A375S, A375R, A2058, and MEWO cells. The gene discussed is BIRC5; the disease is melanoma.